Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: An in-silico study

BMC Bioinformatics

Volumn 12, Issue , 2011, Pages

  Liu, Qi ^a   Zhou, Han ^a   Liu, Lin ^a   Chen, Xi ^b   Zhu, Ruixin ^a   Cao, Zhiwei ^a  

^a TONGJI UNIVERSITY   (China)

^b Carnegie Mellon University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITIES; COMPOUND STRUCTURES; MACHINE LEARNING TECHNIQUES; MOLECULAR MECHANISM; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP STUDIES; REGULARIZED OPTIMIZATIONS; REVERSE TRANSCRIPTASES; STRUCTURE-ACTIVITY;

AMINO ACIDS; BINDING ENERGY; DESIGN; DRUG THERAPY; GRADIENT METHODS; HEALTH RISKS; LEARNING SYSTEMS;

VIRUSES;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT;

ARTICLE; BIOLOGICAL MODEL; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIXED INFECTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; COINFECTION; DRUG DESIGN; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79960562727     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-12-294     Document Type: Article

References (37)

1. Jorissen RN, Reddy G, Ali A, Altman MD, Chellappan S, Anjum SG, Tidor B, Schiffer CA, Rana TM, Gilson MK. Additivity in the analysis and design of HIV protease inhibitors. J Med Chem 2009, 52(3):737-754. 10.1021/jm8009525, 2715819, 19193159.
2. Johnston MI, Hoth DF. Present status and future prospects for HIV therapies. Science 1993, 260(5112):1286. 10.1126/science.7684163, 7684163.
3. Maier I, Wu GY. Hepatitis C and HIV co-infection: a review. Transfusion 1992, 7(20):2.
4. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. The Lancet Infectious Diseases 2004, 4(7):437-444. 10.1016/S1473-3099(04)01059-X, 15219554.
5. Solov'ev VP, Varnek A. Anti-HIV Activity of HEPT, TIBO, and Cyclic Urea Derivatives: Structure- Property Studies, Focused Combinatorial Library Generation, and Hits Selection Using Substructural Molecular Fragments Method. J Chem Inf Comput Sci 2003, 43(5):1703-1719.
6. Iyer M, Hopfinger AJ. Treating Chemical Diversity in QSAR Analysis: Modeling Diverse HIV-1 Integrase Inhibitors Using 4D Fingerprints. J Chem Inf Model 2007, 47(5):1945-1960. 10.1021/ci700153g, 17661457.
7. Patel PD, Patel MR, Kaushik-Basu N, Talele TT. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors. J Chem Inf Model 2008, 48(1):42-55. 10.1021/ci700266z, 18076152.
8. Nittoli T, Curran K, Insaf S, DiGrandi M, Orlowski M, Chopra R, Agarwal A, Howe AYM, Prashad A, Floyd MB. Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. J Med Chem 2007, 50(9):2108-2116. 10.1021/jm061428x, 17402724.
9. Harper S, Avolio S, Pacini B, Di Filippo M, Altamura S, Tomei L, Paonessa G, Di Marco S, Carfi A, Giuliano C. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J Med Chem 2005, 48(14):4547-4557. 10.1021/jm050056+, 15999993.
10. Chen KX, Nair L, Vibulbhan B, Yang W, Arasappan A, Bogen SL, Venkatraman S, Bennett F, Pan W, Blackman ML. Second-Generation Highly Potent and Selective Inhibitors of the Hepatitis C Virus NS3 Serine Protease. J Med Chem 2009, 52(5):1370-1379. 10.1021/jm801238q, 19196021.
11. Arasappan A, Padilla AI, Jao E, Bennett F, Bogen SL, Chen KX, Pike RE, Sannigrahi M, Soares J, Venkatraman S. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile. Journal of medicinal chemistry 2009, 52(9):2806-2817. 10.1021/jm801616e, 19371095.
12. Bogen SL, Pan W, Ruan S, Nair LG, Arasappan A, Bennett F, Chen KX, Jao E, Venkatraman S, Vibulbhan B. Toward the Back-Up of Boceprevir (SCH 503034): Discovery of New Extended P4-Capped Ketoamide Inhibitors of Hepatitis C Virus NS3 Serine Protease with Improved Potency and Pharmacokinetic Profiles. Journal of medicinal chemistry 2009, 52(12):3679-3688. 10.1021/jm801632a, 19456105.
13. Jenwitheesuk E, Horst JA, Rivas KL, Van Voorhis WC, Samudrala R. Novel paradigms for drug discovery: computational multitarget screening. Trends in pharmacological sciences 2008, 29(2):62-71. 10.1016/j.tips.2007.11.007, 18190973.
14. Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Current Opinion in Pharmacology 2004, 4(5):437-446. 10.1016/j.coph.2004.07.005, 15351347.
15. Reddy G, Ali A, Nalam MNL, Anjum SG, Cao H, Nathans RS, Schiffer CA, Rana TM. Design and Synthesis of HIV-1 Protease Inhibitors Incorporating Oxazolidinones as P2/P2 'Ligands in Pseudosymmetric Dipeptide Isosteres. J Med Chem 2007, 50(18):4316-4328. 10.1021/jm070284z, 17696512.
16. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. Substrate Shape Determines Specificity of Recognition for HIV-1 Protease:: Analysis of Crystal Structures of Six Substrate Complexes. Structure 2002, 10(3):369-381. 10.1016/S0969-2126(02)00720-7, 12005435.
17. Chellappan S, Kairys V, Fernandes MX, Schiffer C, Gilson MK. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins: Structure, Function, and Bioinformatics 2007, 68(2):561-567.
18. Schultz AK, Zhang M, Leitner T, Kuiken C, Korber B, Morgenstern B, Stanke M. A jumping profile Hidden Markov Model and applications to recombination sites in HIV and HCV genomes. BMC bioinformatics 2006, 7(1):265. 10.1186/1471-2105-7-265, 1525204, 16716226.
19. Tan SL, Pause A, Shi Y, Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. Nature Reviews Drug Discovery 2002, 1(11):867-881. 10.1038/nrd937, 12415247.
20. Franciscus A. Hepatitis C treatments in current clinical development.
21. Leach AR. Molecular modelling: principles and applications. 2001, Addison-Wesley Longman Ltd.
22. Tomasselli AG, Heinrikson RL. Targeting the HIV-protease in AIDS therapy: a current clinical perspective1. Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular Enzymology 2000, 1477(1-2):189-214.
23. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Journal of Antimicrobial Chemotherapy 65(6):1079.
24. Chen X, Pan W, Kwok JT, Carbonell JG. Accelerated gradient method for multi-task sparse learning problem. IEEE 2009, 746-751.
25. Labute P. A widely applicable set of descriptors. Journal of Molecular Graphics and Modelling 2000, 18(4-5):464-477. 10.1016/S1093-3263(00)00068-1, 11143563.
26. Xu J, Stevenson J. Drug-like index: a new approach to measure drug-like compounds and their diversity. J Chem Inf Comput Sci 2000, 40(5):1177-1187.
27. Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Current Topics in Medicinal Chemistry 2008, 8(18):1555-1572. 10.2174/156802608786786624, 19075767.
28. Cortes A, Cascante M, Cardenas ML, Cornish-Bowden A. Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data. Biochemical Journal 2001, 357(Pt 1):263. 1221950, 11415458.
29. Wu G, Yuan Y, Hodge CN. Determining appropriate substrate conversion for enzymatic assays in high-throughput screening. Journal of Biomolecular Screening 2003, 8(6):694. 10.1177/1087057103260050, 14711395.
30. Liu Q, Xu Q, Zheng VW, Xue H, Cao Z, Yang Q. Multi-task learning for cross-platform siRNA efficacy prediction: an in-silico study. BMC bioinformatics 11(1):181.
31. Liu Q, Che D, Huang Q, Cao Z, Zhu R. Multi-target QSAR Study in the Analysis and Design of HIV-1 Inhibitors. Chinese Journal of Chemistry 28(9):1587-1592.
32. Selassie C, Verma RP. History of quantitative structure-activity relationships. Burger's Medicinal Chemistry and Drug Discovery 2003, 1. Drug Discovery, John Wiley&Sons, Inc, sixth.
33. Duchi J, Shalev-Shwartz S, Singer Y, Chandra T. Efficient projections onto the l 1-ball for learning in high dimensions. ACM 2008, 272-279.
34. Weaver S, Gleeson MP. The importance of the domain of applicability in QSAR modeling. J Mol Graph Model 2008, 26(8):1315-1326. 10.1016/j.jmgm.2008.01.002, 18328754.
35. Tropsha A, Gramatica P, Gombar VK. The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models. QSAR & Combinatorial Science 2003, 22(1):69-77. 10.1002/qsar.200390007, 21788139.
36. Pan SJ, Yang Q. A survey on transfer learning. IEEE Transactions on Knowledge and Data Engineering 2009,
37. Darnag R, Schmitzer A, Belmiloud Y, Villemin D, Jarid A, Chait A, Seyagh M, Cherqaoui D. QSAR Studies of HEPT Derivatives Using Support Vector Machines. QSAR & Combinatorial Science 2009, 28(6-7):709-718. 10.1002/qsar.200810166, 21788139.